Array Biopharma, Inc. (NASDAQ: ARRY) reported Q3 EPS of ($0.20), $0.01 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $9.4 million.

For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.